Claims
- 1. A benzothiazole derivative represented by the following formula (I): ##STR69## wherein R.sup.1 is a group represented by the formula: ##STR70## wherein p is an integer of from 1 to 4, or a group represented by the formula: ##STR71## wherein R.sup.7 represents a lower alkyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a group represented by the formula: ##STR72## wherein p is an integer of from 1 to 4, or a group represented by the formula: ##STR73## wherein R.sup.7 represents a lower alkyl group; R.sup.4 represents a hydrogen atom, a lower alkyl group, a phenyl group, or a group represented by the formula: ##STR74## wherein R.sup.7 represents a lower alkyl group, with the proviso that R.sup.3 and R.sup.4 are not both hydrogen atoms; or
- R.sup.3 and R.sup.4 may form a benzene ring together with the carbon atoms to which they are bound;
- R.sup.2 represents a hydrogen atom or a protective group of a hydroxyl group; and
- R.sup.5 and R.sup.6 are either same or different and each represents a hydrogen atom, a lower alkyl group, a group represented by the formula: ##STR75## wherein r is an integer of from to 4, or an acyl group; or a pharmacologically acceptable salt thereof.
- 2. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.3 is a lower alkyl group.
- 3. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.4 is a lower alkyl group.
- 4. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is a group represented by the formula: ##STR76## wherein p is an integer of from 1 to 4.
- 5. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.3 is a group represented by the formula: ##STR77## wherein p is an integer of from 1 to 4.
- 6. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.2 is a hydrogen atom.
- 7. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein one of R.sup.5 and R.sup.6 is a hydrogen atom while the other is a lower alkyl group.
- 8. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein one of R.sup.5 and R.sup.6 is a hydrogen atom while the other is a group represented by the following formula: ##STR78## wherein r is an integer of from 1 to 4.
- 9. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.3, R.sup.4 and R.sup.5 are each a lower alkyl group, R.sup.1 is a group represented by the formula: ##STR79## wherein p is an integer of from 1 to 4; and R.sup.2 and R.sup.6 are each a hydrogen atom.
- 10. The benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 9, wherein R.sup.1 is a 3-pyridylmethyl group.
- 11. A pharmacological composition which comprises a therapeutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 and a pharmacologically acceptable vehicle.
- 12. A method for treating a disease in which 5-lipoxygenase activity is raised, comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the activity of the 5-lipoxygenase is raised.
- 13. A method for treating a disease in which thromboxane synthetase activity is raised; comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the activity of thromboxane synthetase is raised.
- 14. A method for treating a disease in which leukotriene synthesis is raised, comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the synthesis of leukotrienes is raised.
- 15. A method for treating a disease in which synthesis of thromboxanes is raised, comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the synthesis of thromboxanes is raised.
- 16. A method for treating inflammatory bowel diseases, comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 a patient suffering from said inflammatory bowel diseases.
- 17. A method for treating ulcerative coliris, comprising administering a pharmaceutically effective amount of the benzothiazole derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said ulcerative colitis.
- 18. The benzothiazole derivative as claimed in claim 1, wherein said benzothiazole derivative is 2-ethylamino-6-hydroxy-4,5-dimethyl-7-(3-pyridylmethyl) benzothiazole or a pharmacologically acceptable salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
3-71480 |
Apr 1991 |
JPX |
|
3-281366 |
Oct 1991 |
JPX |
|
Parent Case Info
This application is a divisional of application Ser. No 07/861,379, filed on Mar. 31, 1992, U.S. Pat. No. 5,300,518, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
1931077 |
Lubs et al. |
Oct 1933 |
|
4873346 |
Anderson |
Oct 1989 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0295656 |
Dec 1988 |
EPX |
0356234 |
Feb 1990 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Ulrich et al, Journal of Medicinal Chemistry, vol. 25, No. 6, pp. 654-657, 1982. |
Lau et al., Journal of Organic Chemistry, vol. 35, No. 12, pp. 4103-4108, 1970. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
861379 |
Mar 1992 |
|